Ready-to-deploy vaccine and antibody plans for emerging viral threats
PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats
['FUNDING_OTHER'] · ALBERT EINSTEIN COLLEGE OF MEDICINE · NIH-11373847
This project will create ready-to-use vaccine and antibody blueprints to help protect people from new dangerous RNA viruses.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBERT EINSTEIN COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (BRONX, UNITED STATES) |
| Trial ID | NIH-11373847 on ClinicalTrials.gov |
What this research studies
Teams from multiple institutions are designing 'plug-and-play' vaccine and therapeutic antibody blueprints for several families of emerging RNA viruses. They will use prototype viruses to study how infections occur, develop optimized vaccine antigens, and generate antibody candidates. The work includes creating RNA vaccine formulations and testing safety and protective effects in laboratory and animal models. Industry partners will help plan manufacturing and regulatory steps so promising candidates can move toward human testing.
Who could benefit from this research
Good fit: People who might later be eligible for clinical trials or willing to donate samples—such as those at higher risk of exposure, healthcare workers, or volunteers for future vaccine studies—would be the most likely candidates for participation.
Not a fit: Patients with health issues unrelated to these virus families or who cannot join future trials are unlikely to see direct benefit from this work.
Why it matters
Potential benefit: If successful, this could speed development and deployment of vaccines and antibody treatments during future outbreaks, helping people get protection faster.
How similar studies have performed: RNA vaccines and monoclonal antibodies showed strong real-world success during COVID-19, but adapting these platform approaches specifically to Nairoviridae, Hantaviridae, and Paramyxoviridae is a newer effort.
Where this research is happening
BRONX, UNITED STATES
- ALBERT EINSTEIN COLLEGE OF MEDICINE — BRONX, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANDRAN, KARTIK — ALBERT EINSTEIN COLLEGE OF MEDICINE
- Study coordinator: CHANDRAN, KARTIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.